Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition

ABSTRACT Background: Agitation is common across neuropsychiatric disorders and contributes to disability, institutionalization, and diminished quality of life for patients and their caregivers. There is no consensus definition of agitation and no widespread agreement on what elements should be included in the syndrome. The International Psychogeriatric Association formed an Agitation Definition Work Group (ADWG) to develop a provisional consensus definition of agitation in patients with cognitive disorders that can be applied in epidemiologic, non-interventional clinical, pharmacologic, non-pharmacologic interventional, and neurobiological studies. A consensus definition will facilitate communication and cross-study comparison and may have regulatory applications in drug development programs. Methods: The ADWG developed a transparent process using a combination of electronic, face-to-face, and survey-based strategies to develop a consensus based on agreement of a majority of participants. Nine-hundred twenty-eight respondents participated in the different phases of the process. Results: Agitation was defined broadly as: (1) occurring in patients with a cognitive impairment or dementia syndrome; (2) exhibiting behavior consistent with emotional distress; (3) manifesting excessive motor activity, verbal aggression, or physical aggression; and (4) evidencing behaviors that cause excess disability and are not solely attributable to another disorder (psychiatric, medical, or substance-related). A majority of the respondents rated all surveyed elements of the definition as “strongly agree” or “somewhat agree” (68–88% across elements). A majority of the respondents agreed that the definition is appropriate for clinical and research applications. Conclusions: A provisional consensus definition of agitation has been developed. This definition can be used to advance interventional and non-interventional research of agitation in patients with cognitive impairment.

[1]  Andrew J. Saykin,et al.  Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease , 2013, Alzheimer's & Dementia.

[2]  Y. Ang,et al.  The impact of neuropsychiatric symptoms on caregiver distress and quality of life in persons with dementia in an Asian tertiary hospital memory clinic , 2013, International Psychogeriatrics.

[3]  Henry Brodaty,et al.  Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future , 2013, Alzheimer's & Dementia.

[4]  A. Swann Activated Depression: Mixed Bipolar Disorder or Agitated Unipolar Depression? , 2013, Current Psychiatry Reports.

[5]  Janet B W Williams Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[6]  K. Josephs,et al.  Neuropsychiatry of corticobasal degeneration and progressive supranuclear palsy , 2013, International review of psychiatry.

[7]  V. Curtis,et al.  Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia , 2013, Current medical research and opinion.

[8]  H. Brodaty,et al.  The Sydney Multisite Intervention of LaughterBosses and ElderClowns (SMILE) study: cluster randomised trial of humour therapy in nursing homes , 2013, BMJ Open.

[9]  C. Lyketsos,et al.  Nonpharmacologic management of behavioral symptoms in dementia. , 2012, JAMA.

[10]  E. Huey,et al.  Diagnosis and Management of Behavioral Issues in Frontotemporal Dementia , 2012, Current Neurology and Neuroscience Reports.

[11]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[12]  K. Langa,et al.  Neuropsychiatric Symptoms and the Risk of Institutionalization and Death: The Aging, Demographics, and Memory Study , 2011, Journal of the American Geriatrics Society.

[13]  C. Ballard,et al.  Management of Neuropsychiatric Symptoms in People with Dementia , 2010, CNS drugs.

[14]  Annalena Venneri,et al.  Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. , 2008, Brain : a journal of neurology.

[15]  N. Herrmann,et al.  Pharmacologic Management of Neuropsychiatric Symptoms of Alzheimer Disease , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[16]  Philip S. Insel,et al.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[17]  E. Kong Agitation in dementia: concept clarification. , 2005, Journal of Advanced Nursing.

[18]  J. Mintzer,et al.  Time for Change: The Role of Nonpharmacological Interventions in Treating Behavior Problems in Nursing Home Residents With Dementia , 2005, Alzheimer disease and associated disorders.

[19]  M. Mega,et al.  Agitation in Alzheimer’s Disease Is a Manifestation of Frontal Lobe Dysfunction , 2003, Dementia and Geriatric Cognitive Disorders.

[20]  B. Lebowitz,et al.  Provisional diagnostic criteria for depression of Alzheimer’s disease: description and review , 2003, Expert review of neurotherapeutics.

[21]  T. Laughren A regulatory perspective on psychiatric syndromes in Alzheimer disease. , 2001, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[22]  P. D. De Deyn,et al.  Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. , 2001, The Journal of clinical psychiatry.

[23]  D. Jeste,et al.  Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[24]  S. Finkel,et al.  Introduction to behavioural and psychological symptoms of dementia (BPSD) , 2000, International journal of geriatric psychiatry.

[25]  B. Draper The International Psychogeriatric Association--ninth congress. 15-20 August 1999, Vancouver, Canada. , 1999, IDrugs : the investigational drugs journal.

[26]  S. Finkel,et al.  Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment , 1997, International Psychogeriatrics.

[27]  B. Reisberg,et al.  Behavioral Disturbances of Dementia: An Overview of Phenomenology and Methodologic Concerns , 1996, International Psychogeriatrics.

[28]  J. Cohen-Mansfield,et al.  A description of agitation in a nursing home. , 1989, Journal of gerontology.

[29]  S H Ferris,et al.  Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. , 1987, The Journal of clinical psychiatry.

[30]  W. Maier,et al.  Diagnostic classification of psychiatric disorders and familial-genetic research , 1999, Dialogues in clinical neuroscience.

[31]  D. Jeste,et al.  Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects. , 2007, Psychopharmacology bulletin.

[32]  K. Brady,et al.  Gabapentin in the treatment of cocaine dependence: a case series. , 2001, The Journal of clinical psychiatry.